Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?
- PMID:7793878
- PMCID: PMC162610
- DOI: 10.1128/AAC.39.3.714
Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?
Abstract
Mersacidin is an antibiotic peptide produced by Bacillus sp. strain HIL Y-85,54728 that belongs to the group of lantibiotics. Its activity in vivo against methicillin-resistant Staphylococcus aureus strains compares with that of the glycopeptide antibiotic vancomycin (S. Chatterjee, D. K. Chatterjee, R. H. Jani, J. Blumbach, B. N. Ganguli, N. Klesel, M. Limbert, and G. Seibert, J. Antibiot. 45:839-845, 1992). Incubation of Staphylococcus simulans 22 with mersacidin resulted in the cessation of growth and slow lysis. Biosyntheses of DNA, RNA, and protein were not affected, whereas incorporation of glucose and D-alanine was inhibited and a regular reduction in the level of cell wall thickness was observed. Thus, unlike type A lantibiotics, mersacidin does not form pores in the cytoplasmic membrane but rather inhibits cell wall biosynthesis. Comparison with tunicamycin-treated cells indicated that peptidoglycan rather than teichoic acid metabolism is primarily affected. Mersacidin caused the excretion of a putative cell wall precursor into the culture supernatant. The formation of polymeric peptidoglycan was effectively inhibited in an in vitro assay, probably on the level of transglycosylation. In contrast to vancomycin, the activity of mersacidin was not antagonized by the tripeptide diacetyl-L-Lys-D-Ala-D-Ala, indicating that on the molecular level its mode of action differs from those of glycopeptide antibiotics. These data together with electron microscopy suggest that mersacidin acts on a novel target, which opens new perspectives for the treatment of methicillin-resistant S. aureus.
Similar articles
- The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.Brötz H, Bierbaum G, Reynolds PE, Sahl HG.Brötz H, et al.Eur J Biochem. 1997 May 15;246(1):193-9. doi: 10.1111/j.1432-1033.1997.t01-1-00193.x.Eur J Biochem. 1997.PMID:9210483
- Effects of the lantibiotic mersacidin on the morphology of staphylococci.Molitor E, Kluczny C, Brötz H, Bierbaum G, Jack R, Sahl HG.Molitor E, et al.Zentralbl Bakteriol. 1996 Jul;284(2-3):318-28. doi: 10.1016/s0934-8840(96)80108-3.Zentralbl Bakteriol. 1996.PMID:8837393
- The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus.Sass P, Jansen A, Szekat C, Sass V, Sahl HG, Bierbaum G.Sass P, et al.BMC Microbiol. 2008 Oct 23;8:186. doi: 10.1186/1471-2180-8-186.BMC Microbiol. 2008.PMID:18947397Free PMC article.
- Antimicrobial mechanism of lantibiotics.Islam MR, Nagao J, Zendo T, Sonomoto K.Islam MR, et al.Biochem Soc Trans. 2012 Dec 1;40(6):1528-33. doi: 10.1042/BST20120190.Biochem Soc Trans. 2012.PMID:23176511Review.
- [Molecular mechanism of inhibition of biosynthesis of peptidoglycan of bacterial cell walls by antibiotics].Torbochkina LI.Torbochkina LI.Antibiotiki. 1970 May;15(5):465-76.Antibiotiki. 1970.PMID:4915727Review.Russian.No abstract available.
Cited by
- Classification and Multifaceted Potential of Secondary Metabolites Produced byBacillus subtilis Group: A Comprehensive Review.Iqbal S, Begum F, Rabaan AA, Aljeldah M, Al Shammari BR, Alawfi A, Alshengeti A, Sulaiman T, Khan A.Iqbal S, et al.Molecules. 2023 Jan 17;28(3):927. doi: 10.3390/molecules28030927.Molecules. 2023.PMID:36770594Free PMC article.Review.
- Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.Mathur H, Field D, Rea MC, Cotter PD, Hill C, Ross RP.Mathur H, et al.Front Microbiol. 2017 Jun 29;8:1205. doi: 10.3389/fmicb.2017.01205. eCollection 2017.Front Microbiol. 2017.PMID:28706513Free PMC article.Review.
- Characterization, distribution, and expression of novel genes among eight clinical isolates of Streptococcus pneumoniae.Shen K, Gladitz J, Antalis P, Dice B, Janto B, Keefe R, Hayes J, Ahmed A, Dopico R, Ehrlich N, Jocz J, Kropp L, Yu S, Nistico L, Greenberg DP, Barbadora K, Preston RA, Post JC, Ehrlich GD, Hu FZ.Shen K, et al.Infect Immun. 2006 Jan;74(1):321-30. doi: 10.1128/IAI.74.1.321-330.2006.Infect Immun. 2006.PMID:16368987Free PMC article.
- Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1.Arguelles Arias A, Ongena M, Devreese B, Terrak M, Joris B, Fickers P.Arguelles Arias A, et al.PLoS One. 2013 Dec 9;8(12):e83037. doi: 10.1371/journal.pone.0083037. eCollection 2013.PLoS One. 2013.PMID:24349428Free PMC article.
- Novel LanT associated lantibiotic clusters identified by genome database mining.Singh M, Sareen D.Singh M, et al.PLoS One. 2014 Mar 12;9(3):e91352. doi: 10.1371/journal.pone.0091352. eCollection 2014.PLoS One. 2014.PMID:24621781Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical